Blood Resolvin D1 is Associated with a Lower Acute Myocardial Infarction Risk

Resolvin D1 (RvD1) is involved in the pathology of acute myocardial infarction (AMI) by regulating inflammation and atherosclerosis.This study aimed to delve into the potential of RvD1 as a diagnostic marker for AMI.A total of 149 AMI patients who underwent percutaneous coronary intervention (PCI) and 30 healthy controls (HC) were enrolled in this study.Blood RvD1 was detected by enzyme-linked immunosorbent assay in AMI patients at baseline and after PCI.Blood RvD1 was also detected in HC after enrollment.The median [interquartile range (IQR)] level of RvD1 was lower in AMI patients [1.04 (0.69-1.56) ng/mL], ST-segment elevation myocardial infarction (STEMI) patients [0.95 (0.61-1.28) ng/mL], and non-STEMI patients [1.47 (0.96-2.69) ng/mL] than in ) ng/mL] (all P<0.001).RvD1 was also decreased in STEMI patients compared with non-STEMI patients (P<0.001).RvD1 had a good ability to discriminate AMI patients from HC [area under the curve (95% confidence interval): 0.815 (0.739-0.892)].RvD1 exhibited acceptable diagnostic performance for AMI when the cutoff values ranged from 1.1 to 2.5 ng/mL, with Youden indexes ranging from 0.406 to 0.498.The Youden index peaked at 0.498 when the cutoff value of RvD1 was 1.2 ng/mL, with a sensitivity of 0.631 and a specificity of 0.867.RvD1 was negatively related to triglycerides (P=0.003) and cardiac troponin I (P=0.012) in AMI patients.RvD1 was increased after PCI compared to its level at baseline in AMI patients (P<0.001).RvD1 is associated with a lower AMI risk, and its level is increased after PCI.